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2352-3042/Copyright ª 2014, ChongqiAbstract The past decade has seen an unprecedented increase in our understanding of the
biology and etiology of head and neck squamous cell carcinomas (HNSCC). Genome-wide
sequencing projects have identified a number of recurrently mutated genes, including unex-
pected alterations in the NOTCH pathway and chromatin related genes. Gene-expression
profiling has identified 4 distinct genetic subtypes which show some parallels to lung squamous
cell carcinoma biology. The identification of the human papilloma virus as one causative agent
in a subset of oropharyngeal cancers and their association with a favorable prognosis has
opened up avenues for new therapeutic strategies. The expanding knowledge of the underlying
molecular abnormalities in this once very poorly understood cancer should allow for increas-
ingly rational clinical trial design and improved patient outcomes.
Copyright ª 2014, Chongqing Medical University. Production and hosting by Elsevier B.V. All
rights reserved.Introduction
Head and neck squamous cell carcinoma (HNSCC) is the
sixth most common malignancy in the world, with an annual
world-wide incidence of over 600,000 cases per year andology and Pathogenesis Pro-
gy, Memorial Sloan-Kettering
ox 22, New York, NY 10065,
(T.A.Chan).
ity of Chongqing Medical
14.07.002
ng Medical University. Production350,000 deaths per year.1 Cancers in the head and neck can
originate from a variety of subsites including the lip, oral
cavity, nasopharynx, oropharynx, and larynx. The most
common causes of head and neck cancers are tobacco and
alcohol, which work synergistically, and are responsible for
70e75% of cases.2,3 In parts of Asia, betel-quid chewing also
plays a significant role in the development of malignancy.4
On a molecular level, these cancers often have p53 muta-
tions and many display chromosomal instability.5
More recently, the human papilloma virus (HPV) has been
shown to promote HNSCC and primarily cause oropharyn-
geal cancers (a sub-site in the head and neck).6 Researchers
have found significant differences in the pathogenesis and
prognosis of HPV-related malignancies and HPV-negativeand hosting by Elsevier B.V. All rights reserved.
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malignances as a separate biologic entity. Unlike HPV-
negative cancers, HPV-related oropharyngeal malignancies
are not as strongly associated with tobacco and alcohol
exposure. They are, instead, related to sexual behavior,
which is a conduit to transmit HPV.7,8 Relative to HPV-
negative malignancies, HPV-positive cancers are associ-
ated with a more favorable prognosis.7,9 The incidence of
HPV-positive cancer is rising, while incidence of HPV-
negative cancers is decreasing.
Treatment of HNSCC is made challenging due to the di-
versity of the anatomic sites in the head and neck and the
critical normal structures that may be near a particular
tumor site. Often, the care of a patient requires a multi-
disciplinary team of surgeons, radiation oncologists, medi-
cal oncologists, nutritionists, gastroenterologists, and
speech and swallowing therapists, amongst others. Treat-
ment options for HNSCC can consist of definitive surgical
resection, definitive chemo-radiation, or a combination of
surgery and chemo-radiation. Despite the availability of
aggressive treatments, the 5-year survival rate for head and
neck malignancies remains relatively poor at 65%, with only
modest gains in the past few years.10
An understanding of the molecular and genetic ab-
normalities leading to oncogenesis in head and neck ma-
lignancies has dramatically increased in the past decade.
Initial attempts to understand the genetic etiology of
head and neck cancers focused on cytogenetic studies.
The development of microarray technology enabled the
classification of HNSCC into distinct types based on gene
expression. More recently, next-generation sequencing
technologies have allowed multiple groups of researchers
to sequence a large number of tumors to identify novel
mutated tumor suppressor genes and oncogenes. An
underlying rationale for these researchers’ genomic
profiling studies was to gain a more thorough under-
standing of the molecular abnormalities in head and neck
cancer to help guide the development of new therapeu-
tics. Before reviewing the major discoveries of each of
these profiling techniques, we will briefly discuss genetic
factors that may pre-dispose individuals to develop
HNSCC.Genetic predisposition to HNSCC
Although most cases of HNSCC are induced by carcinogens
or viral infection, a small fraction of cases are familial in
nature. The syndromic etiology with the clearest link of an
increased risk of HNSCC is Fanconi anemia, an autosomal
recessive genomic-instability syndrome associated with
bone marrow failure, leukemia, congenital defects, and
sensitivity to cross-linking agents.11 Cohort studies of Fan-
coni anemia patients have demonstrated a highly elevated
risk of HNSCC with the ratio of the observed number of
HNSCC cases to expected number of cases ranging between
240 and 706.12e14 Treatment of these patients requires care
as they are sensitive to common chemotherapeutics used in
HNSCC and may be sensitive to radiotherapy as well,
although this latter point is controversial.15 Rare clusters of
HNSCC have also been reported in families with germ-line
mutations in CDKN2A and ATR.16,17In non-syndromic families, initial caseecontrol studies
demonstrated a genetic predisposition, with first-degree
relatives having a 3.5 fold increased risk of HNSCC. Subse-
quent pooled analysis, however, led to an odds ratio of
1.7.18e21 It has been hypothesized that genetic differences
in pathways such as DNA repair, carcinogen metabolism,
and cell cycle control may increase the risk of carcino-
genesis from exposure to tobacco or alcohol.22 Phenotypic
differences in these processes in lymphocytes from HNSCC
patients and controls have been identified.23,24 Candidate
gene-based studies have generated mixed results, with the
notable exception of a nearly 9000 patient series that
identified SNPs in multiple alcohol dehydrogenase (ADH)
genes associated with a decreased risk of an upper aero-
digestive malignancy.25e28 Subsequently, a genome-wide
association study in upper aero-digestive malignancies
validated the ADH SNPs and also identified a SNP in HELQ (a
DNA repair gene) as being associated with risk of malig-
nancy. Cumulatively, these SNPs only accounted for 4% of
the familial risk.29Expression profiling
One of the first attempts to genomically profile HNSCC was
with mRNA profiling. Unsupervised hierarchal clustering of
the transcriptome of 60 HNSCC patients30 identified 4 sub-
types e basal, atypical, mesenchymal type, and classical
subtype e which have subsequently been verified by other
investigators.31 Classical tumors exhibit alterations in
expression of genes involved in oxidative stress, such as
KEAP/NFEL2. The atypical cluster is enriched with HPV-
positive tumors (discussed further below). Mesenchymal
tumors demonstrate an elevation in expression of genes
associated with epithelial-to-mesenchymal transition
(EMT). The basal subtype has an expression pattern similar
to basal epithelial cells in airways and is named for its
similarity to the basal type in squamous cell carcinoma of
the lung.
The four subtypes do not show a significant correlation
with age or smoking status, but do appear to be related to
site of origin.31 Still, each anatomic subsite, except for
hypopharyngeal cancer, is present to some extent in each
cluster, suggesting that expression-based subtypes reflect a
biology that, at least in part, transcends anatomic sub-site.
Whether these subtypes provide prognostic information in
and of themselves is unclear at present, given the small size
of the studies to date examining the issue. Initial reports
indicated these expression-based groups may predict for
recurrence-free survival, however, those findings have not
been subsequently replicated.31 Of significant interest is
that there is a strong correlation between each of these
subtypes and their corresponding expression-based sub-
types in squamous cell carcinoma of the lung.31 That is, the
basal, mesenchymal, and classical subtypes in HNSCC
strongly correlate with the basal, secretory, and classical
subtypes in lung cancer. In other malignancies such as
breast cancer and glioblastoma, expression-based subtypes
have helped guide translational research as well as thera-
peutic development; their utility in HNSCC remains to be
determined but they potentially could guide research
efforts.32,33
Table 1 Major sequencing studies.
Stransky Agrawal Pickering India
ICGC
N 74 32 40 50
Disease sitesa OC, OP, H, L, SC OC, OP, L, H OC OC
Smokers 89% 75% 78.6% 96%
HPV positivity 14% 25% 2.5% 26%
Mean coverage 150 77d 119 38d
Whole exome 72 32 40 50
Whole genome 2 0 0 0
Additional tumors with limited sequencing NA 88 NA 60
Significantly mutated genesb 39 6 53 10
Mutations per MB (HPVþ; HPV) 2.28; 4.83 4.8; 20.6 NRc 4.07; 3.36
a Sites: OC: Oral Cavity, OP: Oropharynx, H: Hypopharynx, L: Larynx; SC sinonasal cavity.
b Significantly mutated here is as determined by authors of paper (some studies included formal statistical testing, while others did
not).
c Not reported.
d Group used multiple sequencing platforms, highest mean coverage is reported.
Table 2 Frequency of selected genes recurrently mutated
in 4 major sequencing studies to date.
Gene Stransky Agrawala Pickering India ICGC
p53 62% 47% 66% 62%
CDKN2A 12% 9.2%
CASP8 8% 10% 34%
FAT1 12% 28% 40%
NOTCH1 14% 15% 9% 16%
HRAS 5% 4% 9% 12%
PIK3CA 8% 6% 11%
MLL2
FBXW7 5%
Red indicates genes were not identified as significant in that
study.
a Did not use formal statistical testing.
Understanding the head and neck cancer genome 77Multiple investigators have developed expression-based
signatures to predict clinical behavior of HNSCC, such as
lymph node metastasis, hypoxia, or radiosensitivity.34e38
Roepman developed a 102 gene signature that is predic-
tive of the propensity for lymph node metastasis which
theoretically could be used to guide decisions regarding
lymph node dissections.34 The predictor, however, was only
able to correctly determine lymph node status in 61 of 82
patients, and the authors noted that this was of only in-
cremental improvement to clinical decision-making. Onken
et al developed an expression signature for nodal metas-
tasis from a mouse model of oral cavity cancer.39 Inter-
estingly, this signature could predict nodal metastasis
development for human oral cavity cancers in a training set
and a small validation set. However, additional validation is
still needed.
Several groups have looked into expression signatures to
identify tumors that are hypoxic, and therefore, likely to be
resistant to radiotherapy. Some groups have looked for
hypoxic gene signatures in head and neck cancers whereas
others have performed combined analysis over multiple
cancers. In general, these signatures have demonstrated
prognostic value in small cohorts.35e37 The hypoxic signa-
ture by the Danish group was used to retrospectively
analyze data from the DANHCA 5 trial, which was a ran-
domized trial of radiotherapy  nimorazole (a hypoxic
radiosensitizer) in HNSCC.40 This group found that the
benefit of nimorazole on local control and DFS was limited
to patients whose tumors were deemed to be “more hyp-
oxic” by their expression signature.41 This suggests that
their signature may be predictive and could help select
patients for future clinical trials using hypoxic sensitizers.
Mutational analysis and alterations in specific
genes and pathways in HNSCC
The first two large-scale sequencing efforts in HNSCC
identified a number of recurrently mutated genes. The
majority of these were in tumor suppressor genes rather
than oncogenes.42,43 Stransky et al performed wholeexome-sequencing on 74 tumor/normal pairs, with 150-fold
mean coverage, while Agrawal et al sequenced 32 tumor/
normal pairs, with a mean coverage of 77-fold and per-
formed targeted follow-up sequencing in an additional 88
patients. For HPV-negative tumors, Stransky et al found a
mutation rate of 4.83 per Mb while Agrawal et al found a
mutation rate of 20.6 per Mb. The large discrepancy be-
tween the two groups may have arisen from differences in
bioinformatics techniques of mutation calling or differ-
ences in coverage of sequencing. Since these initial studies,
two other groups have looked at mutations specifically in
oral cavity cancers44,45 (Table 1 for study details).
In a pan-cancer analysis, Stratton and colleagues iden-
tified HNSCC as possessing the 9th highest average muta-
tional load out of 30 tumor types studied, with patients
having a range of mutations from less than 1 mutation per
Mb to over 100 mutations per Mb.46 They identified several
active mutational processes in HNSCC, including mutations
due to tobacco exposure, aging, UV light, and alterations in
the apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like (APOBEC) enzymes. Multiple groups have
found signatures of tobacco exposure in HNSCC, which
78 N. Riaz et al.often include guanosine-to-thymidine transversions.43,46
Although alterations in APOBEC have been shown to cause
mutations in other malignancies, most prominently breast
cancer, it is not clear these enzymes are active in HNSCC as
of yet.47 Instead of looking at the type of mutations, Mroz
et al used sequencing data to estimate tumor heterogene-
ity, which they called the mutant-allele tumor heteroge-
neity (MATH) score. This score was prognostic in both HPV-
positive and HPV-negative patients.48
In HPV-negative tumors, the predominant finding from
these sequencing efforts was that a large number of tumor
suppressor genes were mutated. The Broad group identified
39 genes with recurrent mutations (q  0.1), whereas the
JHU group identified 6 genes with mutations in more than
4% of their study (Table 2). Mutations and other genomic
alterations in individual genes and key pathways are
reviewed individually below. Alterations in selected path-
ways are summarized in Fig. 1. Of the non-coding muta-
tions, an interesting one occurs in the promoter of TERT in
nearly 20% of HNSCC, resulting in increased expression of
telomerase.49
TP53
Long before the era of genome sequencing, TP53 had been
recognized as a frequently mutated gene in HNSCC, with
modern series estimating 46e73% of HNSCC cases having a
mutation.42e44,50e53 TP53 is a tumor suppressor gene that
functions primarily as a transcription factor and regulates
the expression of hundreds of downstream target genes in
response to a variety of cellular stresses.54,55 It is composedFigure 1 Alterations in selected pathways in head and neck squ
quency of amplification. Blue: Frequency of deletion. (A) Mitogen
Signaling. (D) Oxidative Stress Response. See text for more details
erences to color in this figure legend, the reader is referred to theof 393 amino acids and contains 4 domains, including a
highly conserved DNA binding domain (DBD). It plays a key
role in a number critical cellular functions, including the
response to DNA damage and oncogenic stress. DNA damage
leads to activation of p53, triggering cell cycle arrest and
an attempt to repair the damage, which if not completed,
can trigger apoptosis or senescence. Mutations in TP53
appear to be acquired early in the pathogenesis of HNSCC
and are present in pre-malignant lesions, suggesting an
important role in early oncogenesis.5,51,56
Most of the missense mutations in TP53 cluster in the
DNA binding domain (DBD) whereas frame-shift and
nonsense mutations are more equally distributed
throughout the gene. One third of the mutations in the DBD
occurs within 6 hotspot residues and result in preventing
binding to DNA.55 Since p53 forms a tetramer, many of
these missense mutations are expected to have a dominant
negative effect.57 Work has indicated that some of these
mutations may also result in a “gain-of-function” pheno-
type, perhaps resulting from expression of other off-target
genes. However, the significance of this remains un-
clear.57,58 Besides mutation, p53 may be inactivated in
other ways such as via MDM2 over-expression or amplifica-
tion (MDM2 is a negative regulator of p53) or deletion of
CDKN2A (negatively regulates MDM2).59 Inactivation of p53
also occurs in HPV-positive tumors and is discussed in more
detail below.
Whether alterations in TP53 are prognostic for overall
survival has been somewhat controversial, with early
studies showing conflicting results.54,60 Limitations in these
earlier studies include the reliance on immunostaining,amous cell cancers. Green: Frequency of mutations. Red: fre-
ic Pathway Alterations. (B) Cell Cycle Alterations. (C) NOTCH
of alterations in each pathway (For interpretation of the ref-
web version of this article.).
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failure to sequence the entire length of the TP53 gene.61,62
More recent and thorough sequencing-based analysis shows
that functional mutations appear to result in significantly
worse outcomes.50,63 For instance, Poeta and colleagues
examined a cohort of 420 patients treated with
surgery  radiotherapy and found that mutations in TP53
were associated with worse overall survival (HR Z 1.4,
p Z 0.009). Patients with truncating mutations or disrupt-
ing mutations in the DNA binding domain had significantly
worse overall survival (HRZ 1.7, p < 0.001), whereas non-
functional mutations alone were not statistically associated
with worse outcomes (HR Z 1.2, p Z 0.16).
As p53 plays an integral role in handling genotoxic stress,
multiple groups found that TP53 mutation results in worse
outcomes in patients uniformly treated with either defini-
tive radiotherapy or post-operative radiotherapy.63e65
However, as TP53 mutations also are prognostic in pa-
tients treated with surgery alone, it is unclear if mutational
status is a true predictive marker. Further, the mechanism
by which p53 promotes radio-resistance remains unclear.66
In cell types susceptible to p53-mediated apoptosis, loss-of-
function would theoretically induce radio-resistance. p53-
mediated apoptosis, however, does not appear to be the
dominant mode of cell death in epithelial tumors.66 Recent
in-vitro work with HNSCC cell lines has suggested that a
subset of p53 mutations may have a gain-of-function
phenotype that promotes senescence and subsequent
radio-resistance.65 Future investigation and more accurate
models will be needed to sort out this controversy.
Cell cycle alterations: CDKN2A, CCND1, and RB1
There is homozygous deletion of CDKN2A in nearly 30% of
HNSCC and the gene is mutated in another 10e20% of
samples, and is frequently subject to LOH.67e69 The ma-
jority of mutations are inactivating and includes frame
shifts, nonsense mutations, and splice site changes. Addi-
tional epigenetic alterations may lead to this gene being
inactivated in up to 80% of tumors.70 One possible strategy
to target this alteration would be to inhibit CDK4/CDK6.
Recently, Palbociclib, a CDK4/6 inhibitor, increased pro-
gression free survival in a cohort of breast cancer patients,
suggesting such an approach may be efficacious.71
The next most commonly altered cell cycle gene in
HNSCC is CCND1, which is amplified in over 20% of tumors.68
CCND1 encodes cyclin D1, which serves as a cofactor for
CDK4 and CDK6 to phosphorylate Rb.72 Again, CDK4/6 in-
hibitor could serve as a method to target these tumors, and
both p16 loss and CCND1 amplification are being investi-
gated as biomarkers in the Palbociclib trial. In the TCGA
data, genetic alteration of one of either CCND1 or CDKN2A
occurs in nearly 60% of cases and in the study by Pickering
et al, it was 94%.45 RB1, the retinoblastoma gene, also
appears to be either mutated or deleted in approximately
5% of patients.
EGFR
Epidermal growth factor receptor (EGFR) is a member of
the HER/erbB family of receptor tyrosine-kinases and is oneof the primary targetable alterations in cancers.73,74 When
activated by binding its ligand, EGFR homodimerizes or
heterodimerizes with other members of the ErbB family,
stimulating its tyrosine kinase activity and leading to auto-
phosphorylation of tyrosine residues in its cytoplasmic
tail.75 This can lead to activation of downstream signaling
cascades including RAS/RAF/MAPK, PI3K/AKT/mTOR (dis-
cussed further below), and/or JAK/STAT. These pathways
are important regulators of proliferation, invasion, angio-
genesis and metastasis.
Therapeutics targeting the EGFR pathway have been
introduced into the clinical setting for a number of malig-
nancies, including HNSCC.76,77 Cetuximab, a chimeric mu-
rine/human monoclonal antibody against EGFR, has
improved overall survival compared to standard treatment
in the locally advanced and metastatic settings, although
adoption in the locally advanced setting remains con-
troversial.78e81 Two humanized antibodies against EGFR,
however, have failed to improve overall survival in either
the recurrent/metastatic setting or the locally advanced
setting.82e84 Similarly two first-generation, small molecule,
tyrosine kinase inhibitors against EGFR (gefitinib and erlo-
tinib) have been disappointing.85e87
Although EGFR is expressed on the surface of the ma-
jority of HNSCC88 tumors and the degree of overexpression
is associated with a worse prognosis, the muddled picture
from therapeutic interventions in the pathway has led to
uncertainty on exactly how this pathway is activated in
HNSCC.89e92 Unlike adenocarcinoma of the lung where
mutations in the kinase domain result in constitutive acti-
vation of EGFR, such mutations are rare in HNSCC.69,93
Amplification of EGFR occurs in a minority of patients and
the presence of amplification or increased IHC expression
has not correlated with efficacy of EGFR inhibition.94,95 Of
note, amplifications in EGFR appear to occur less frequently
in HPV-positive patients, although the therapeutic impli-
cations of this are unclear.
The molecular and clinical trial results suggest that
perhaps cetuximab’s efficacy is mediated more by its
antibody-dependent cell-mediated cytotoxicity then
blockade of the EGFR pathway.76,96,97 Alternatively, resis-
tance to EGFR inhibition may occur quickly by up-regulation
of other erbB receptors, such as ERBB2 (HER2/NEU).98
Strategies addressing both these possibilities are being
actively pursued clinically with the development of pan-
erbB inhibitors and monoclonal antibodies as well as the
pairing of cetuximab with various immune check-point in-
hibitors in development.PI3K/AKT/mTOR
PIK3CA is the 2nd most commonly mutated gene across
human cancers and alterations in this pathway are thought
to play an important role in cancer cell growth, survival,
and metabolism.99,100 The PI3K family of kinases consists of
three classes, with class IA being most frequently involved
in cancer. Activation of PI3K leads to phosphorylation of
phosphatidylinositols (PIP2, a second messenger) and sub-
sequent activation of AKT, one of the main effectors of PI3K
signaling.100 Activated forms of AKT have been found in the
majority of HNSCC tumors analyzed by tissue microarrays.88
80 N. Riaz et al.AKT further activates mTOR, which is also responsible for
integrating cellular signals regarding nutrient levels,
cellular energy stores, and stress. One mechanism of PI3K
activation in HNSCC is by receptor-tyrosine kinases, such as
EGFR. Although EGFR cannot directly active PI3K, if EGFR
heterodimerizes with ERBB3 it can subsequently activate
PI3K signaling.101
Another mechanism of activation of PI3K pathway in
HNSCC involves mutation, with mutations occurring in PI3K
catalytic subunit, p110a (encoded by PIK3CA gene).
Approximately 20% of tumors have mutations in PIK3CA,
however these mutations occur much more commonly in
HPV-positive tumors compared to HPV-negative tumors.68
Mutations often occur in one of two hotspot locations in
the kinase or helical domain and promote constitutive
signaling through the pathway.102 Further, PIK3CA is
amplified in 20% of HNSCC overall. PTEN loss or mutation
occurs in 3% of HNSCC. PTEN encodes a phosphatase that
shuts off PI3K signaling by dephosphorylating PIP3 to PIP2.
Genomic alterations in other members of the PI3K pathway
typically occur at frequencies of less than 5% in HNSCC.
Multiple therapeutic agents that target this pathway are
under investigation in both the upfront and metastatic/
recurrent setting. In general, agents targeting this pathway
include sole PI3K inhibitors (isoform selective and pan-
inhibitors), dual PI3K-mTOR inhibitors, AKT inhibitors, and
mTOR inhibitors. In other malignancies, responses to these
drugs as single agents have been disappointing and perhaps
suggest the development of feedback loops counteracting
inhibition.103 Further, initial experience with dual PI3K-
mTOR agents appear to be limited by toxicity. To-date,
however, experience in HNSCC remains limited and trials
are presently on-going.77NOTCH1/p63/FBXW7
The discovery of recurrent mutations in NOTCH1 was one of
the key novel findings of the initial HNSCC exome-
sequencing projects.42,43 Notch1 is a transmembrane re-
ceptor that plays a role in cell differentiation and embry-
onic development.104,105 Signaling is thought to be
mediated by cell-to-cell contact, enabling binding of Notch
to one of five known ligands. After receptor activation by
ligand binding, a cascade of proteolytic cleavages take
place that result in the release of Notch1’s intracellular
domain (NICD). NICD subsequently translocates to the nu-
cleus where it interacts with CBF1 (CSL) and mastermind-
like (MAML1) leading to transcriptional activation of mul-
tiple genes. Well characterized genes under control of this
pathway include the HES and HRT family of genes, notch
ligands, CCND1, MYC, and others.
Notch appears to be able to function as either a tumor
suppressor or an oncogene depending on cell context. In
TCGA data, NOTCH1 is mutated in 18.6% of cases, with over
35% of mutations leading to a frameshift or nonsense
codon.68 The majority of missense mutations appear in EGF-
like domain repeats, which are important for ligand binding.
This pattern of mutations has suggested that Notch’s role in
HNSCC may be as a tumor suppressor gene, although the
exact mechanism of tumor suppression remains unclear. In a
murine model, deletion of Notch1 results in hyperplasia andcarcinogen-induced skin cancer, supporting a tumor sup-
pressor function.106 Similar loss-of-function mutations have
been seen in cutaneous SCC and lung SCC and cell-based
testing of mutations in the EGF-like domain have demon-
strated loss of signaling.107 In contrast, Notch1 mutations
are oncogenic in T-cell acute lymphoblastic leukemia and
cause ligand-independent cleavage of Notch1, ultimately
leading to constitutive activation.108 Notch’s oncogenic
functions are thought to be mediated by prompting cell
cycle progression and inhibition of apoptosis.105
The other Notch receptors are mutated in 2e4% of cases
with a roughly similar mutational spectrum. In keratino-
cytes of both human and mouse origin, Notch1 signaling
interacts in a negative feedback loop with TP63. TP63 is a
p53 family member gene, which has a role in keratinocyte
cell fate determination. TP63 is found amplified in 20% of
tumors in the TCGA set and interestingly, amplifications
appear to be mutually exclusive with NOTCH1 mutation
(p Z 0.053).68 FBXW7 is ubiquitin ligase that targets Notch
for degradation and is found mutated in 4.7% of cancers of
HNSCC.109 FBXW7 may have a role outside of Notch
signaling, as it targets many other known oncogenes
including cyclin E, MYC, and JUN.Oxidative stress response: NRF2/KEAP1/CUL3
Genes involved in oxidative stress are altered by mutation
or copy number change in nearly 20% of HNSCC, and by IHC,
NRF2 is overexpressed in 90% of tumors.68,110 NRF2 (enco-
ded by the NFE2L2 locus) is a transcription factor that ac-
tivates the cellular antioxidant response.111 It is typically
constitutively expressed under basal conditions and kept in
the cytoplasm and degraded by KEAP1 and CUL3. CUL3 is a
core component of an E3 ubiquitin ligase complex, which
relies on KEAP1, a substrate specific adaptor, to success-
fully ubiquinate NRF2 and promote its degradation. The
interaction between NRF2 and KEAP1 is mediated by NRF2’s
Neh2 domain and KEAP1’s Kelch/DGR domain. In the pres-
ence of oxidative stress, the interaction between KEAP1
and NRF2 is inhibited, leading to the accumulation of NRF2
in the cytoplasm, subsequent translocation to the nucleus,
and thereafter transcriptional activation of its target.
Increased activation of NRF2 may promote cancer cell
growth and protect against cytotoxic therapies.111
In HNSCC, NRF2 is mutated in 6% of patients and
amplified in another 6%. Mutations are clustered in the
Neh2 domain, specifically in two motifs important for
binding with Keap1. The mutations appear to be gain-of-
function mutations which inhibit interaction with KEAP1,
and subsequently lead to an up-regulation of NRF2.112
KEAP1 is mutated in 4% of tumors and rarely homozygous-
ly deleted. The majority of mutations are missense muta-
tions and they occur both in domains involved with binding
to NRF2 and those responsible for binding to CUL3. These
also presumably lead to increased cytoplasmic NRF2, and
subsequent activation of the pathway. Lastly, CUL3 is
mutated or deleted in approximately 6% of patients.
In the TCGA data set, genomic alterations in the NRF2
pathway have correlated with worse overall survival.113
Although not yet validated in another HNSCC cohort, al-
terations in the NRF2 pathway may be prognostic in other
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comes would be resistance to cytotoxic treatments. Multi-
ple studies have shown that elevated NRF2 levels lead to
chemoresistance in a variety of cancer cell lines that ap-
pears to be reversible with siRNA inhibition of
NRF2.111,115,116 Similarly, NRF2 alterations as determined by
expression signature also correlate with resistance to
radiotherapy in cell-line models.117
Chromatin related genes: MLL2, NSD1, EP300, and
other epigenetic changes
The discovery of recurrent mutations in chromatin modi-
fying genes was one of the major discoveries of cancer
sequencing projects in general. In HNSCC, several chro-
matin related genes are recurrently mutated, and at least
one of these genes is mutated in 32% of cases. Chromatin
consists of proteins and DNA and facilitates the packaging
of genomic DNA within the nucleus. The basic functional
unit is a nucleosome, which consists of a histone octamer
and 147 bp of DNA. Chromatin modifying genes can cova-
lently modify histone proteins, which alters the structure of
the nucleosome or alternatively alter DNA.118 These modi-
fications play a critical role in regulating DNA-based pro-
cesses, such as transcription and DNA repair.
MLL2 (aka KMTD2) is a histone methyltransferase that is
mutated in 19% of HNSCC. Over 50% of the mutations lead to
a frame-shift, truncation or splice site alteration, suggest-
ing a tumor suppressor function. MLL2 can methylate
several lysine residues on histones, including H3K4, which is
often associated with positive gene regulation. In leuke-
mia’s, MLL translocations are quiet common and their role
in carcinogenesis is much better understood than the role
of the more recently discovered MLL2 point muta-
tions.119,120 NSD1 is another histone methyltransferase that
is mutated in 10% of patients, with, again, a strong bias
towards truncating and nonsense mutations.
EP300 is histone acetyltransferase that is mutated in 7% of
HNSCC. EP300 and its paralog CBP (CREB-binding protein) are
transcriptional co-activators, which share 75% sequence sim-
ilarity and although they have some distinct roles, they share
many functions.121 Acetylation of histones by EP300 leads to
relaxing the superstructure of chromatin and enables the
transcription of proximal genes. EP300 can also directly
interact with a wide range of transcription factors, pro-
proliferation proteins, and tumor suppressors directly,
including c-MYC, c-MYB, CREB, c-JUN, c-FOS, p53, STAT1,
BRCA1, and SMAD homologous proteins. Given its cooperation
with such a wide variety of proteins, it can promote opposing
cellular processes depending on cell type and context.
FAT1/CASP8
Clustering analysis of mutations reported by the Interna-
tional Cancer Genome Consortium (ICGC) demonstrated
that FAT1 and CAPS8 mutations may define a distinct sub-
type of HNSCC.44 FAT1 is mutated in 23% of tumors, with a
predominance of nonsense and frame-shift mutations,
suggesting a tumor suppressor function. FAT1 encodes a
large transmembrane protein, a protocadherin, which
contains 30þ cadherin repeats as well as 4e5 EGF-likedomains.122 FAT1 is thought to suppress cancer cell growth
by playing a role in Wnt signaling by binding to b-catenin
and limiting its ability to translocate to the nucleus.123
Truncating mutations would inhibit this functionality and
promote tumor cell growth. Of note, the FAT family of
genes (FAT1-4) are also mutated in glioblastoma, colorectal
cancer, gastric, ovarian, and pancreatic cancers. CASP8 is
mutated in 9% of HNSCC and encodes a caspase that plays
an important role in programmed cell death (apoptosis).
CASP8 is specifically involved in the extrinsic pathway of
apoptosis signaling and is activated by membrane bound
receptors such as Fas and TNF.124 Upon activation, Casp-8
triggers the execution phase of apoptosis.Chromosomal instability and copy number
alterations
Among HPV-negative HNSCC, 80% display significant chro-
mosomal instability and over 40% of tumors have undergone
whole genome duplication.5,45,125 The mechanisms under-
lying this instability are unclear, but include both alter-
ations at the chromosomal arm-level and smaller focal
alterations (megabase-pair in size).126 The amount of
chromosomal instability is known to vary between gene-
expression defined molecular subtypes.31 On average, an
individual tumor will have 7.3 arm-level alterations and 16
focal alterations.45 TCGA and others have identified a large
number of recurrent alterations, including 12 arm-level
amplification events, 14 arm-level deletions, 26 focal am-
plifications, and 49 focal deletions.69 Some of the most
commonly lost regions include 3p, 4p, and 9p, whereas
those commonly gained include 3q, 7p, and 8q.127,128
Califano and colleagues studied 87 lesions e including
hyperplasia, dysplasia, carcinoma in situ, and invasive can-
cer e using microsatellite analysis to determine which
chromosomal losses occurred early in carcinogenesis.129
These investigators identified losses on 3p and 9p as early
events that often occur in premalignant lesions. Chromo-
some 9p contains several tumor suppressor genes, the most
notable being CDNK2A, which is involved in cell cycle regu-
lation as discussed previously. The tumor suppressor(s) on 3p
responsible for oncogenesis in HNSCC remains unclear.130
Recent genomic analysis of squamous cell carcinoma of the
esophagus also identified commondeletions in 3p and 9p, and
overall demonstrated a very similar copy number landscape
to HNSCC, suggesting a close molecular relationship.131
Increasing levels of chromosomal instability in pre-
malignant lesions have been associated with an increased
risk of progression to malignant disease in multiple retro-
spective studies.132e134 Across a variety of malignancies,
once cancer has already developed, increasing chromo-
somal instability also appears to be associated with worse
outcome.135 Similarly, in head and neck cancer, increasing
chromosomal instability has been associated with a worse
outcome and a more severe malignant phenotype in mul-
tiple studies, including worse overall survival and higher
risk of lymph node metastasis.136e138 In terms of predicting
response to treatment, one small case control study
compared the copy number profile of tumors sensitive to
chemoradiotherapy vs. those that were resistant and found
a difference in the patterns of gains and losses.139
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Human Papillomavirus (HPV) family of viruses are double-
stranded DNA viruses with a propensity to infect squamous
epithelium.140,141 The HPV family is composed of both low
and high-risk strains, which is determined by a strain’s
ability to lead to malignant progression. HPV has long been
known to induce malignancies such as cervical, anal, and
vulvar cancers. Definitive evidence linking HPV as a causa-
tive agent in oropharyngeal cancer didn’t emerge until the
turn of the century.6 Since then, it has become clear that
HPV-related oropharyngeal cancers are a distinct entity
with a better prognosis compared to traditional smoking
and alcohol related head and neck cancers.9 Further,
epidemiologic trends have suggested a dramatic increase of
HPV-related malignancies over the past two decades, with
the primary risk factor relating to sexual behavior.7,142
HPV16 is the main subtype associated with HNSCC,
although a number of other subtypes have also been re-
ported.7,142,143 The role of HPV in the pathogenesis of non-
oropharyngeal head and neck cancers remains unclear at
present and is an area of active investigation.
The HPV genome consist of 8000 basepairs and is divided
into 3 segments, an early coding region (E), a late coding
region (L), and a long control region (LCR).141 The early and
late regions contain genes important for different parts of the
viral life cycle whereas the LCR contains regulatory elements
important for replication and transcription. In cancer, the
HPV genome can exist either in an episomal form or inte-
grated into the host genome. The viral load and transcription
of HPV-related genes in tumors can vary on the order of
several magnitudes between different tumors.143,144 Inte-
gration into the host genome was thought to favor common
fragile sites, but can occur randomly. Recent work has sug-
gested recurrent insertions in RAD51 and ERBB2.143,145 Inte-
gration is also thought to promote oncogenesis.
HPV contains two oncogenes, E6 and E7, that inactivate
p53 and Rb respectively and are thought to be important
mediators in producing a malignant phenotype. E6 reduces
p53 activity by binding to E6-AP (UBE3A), a ubiquitin-
protein ligase, and targeting p53 for ubiquitination and
degradation.146 E6 can also promote transcription of hTERT,
facilitating immortalization of cells. Inhibition of Rb by E7
leads to cell cycle progression as discussed above (see Cell
Cycle alterations). E7 inhibits Rb by facilitating ubiquiti-
nation and degradation of the protein. Although the E7
protein from low-risk HPV serotypes is also able to bind to
Rb, E7 from high-risk HPV serotypes is much more efficient.
Both E6 and E7 also interact with a variety of other host
proteins that may also play a role in oncogenesis.141
Given their distinct etiology, the mutational, expression,
and copy number profiles of HPV-related cancers are
distinct from their HPV-negative counterparts. For
instance, both of the initial sequencing projects demon-
strated 2e4 fold less mutations per megabase for HPV-
positive tumors compared to their HPV-negative counter-
parts.42,43 The Indian ICGC sequencing project did not
identify a difference in mutation rate between HPV-
positive and negative tumors. However their samples con-
sisted entirely of oral cavity tumors, where the role of HPV
in the underlying pathogenesis of malignancy remainsunclear.44 Similarly, which genes are mutated is strongly
influence by whether or not the malignancy is HPV-related.
For example, p53 is almost never mutated in HPV-related
malignancies, as p53 is inhibited by E6. In addition, muta-
tions in PIK3CA appear to be more common in HPV-positive
malignancies compared to HPV-negative malignancies (see
above). In terms of expression profiling, HPV-related ma-
lignancies cluster with atypical tumors; however, not all
atypical tumors are HPV-related.31
As HPV-positive tumors have a better prognosis, a num-
ber of clinical trials are underway investigating various
ways of de-escalating treatment to reduce morbidity of
treatment. The molecular differences between HPV-
positive and negative tumors clearly play a role in their
prognosis and will also help guide de-escalation trial design.
For instance, some have found an inverse relationship be-
tween HPV and the presence of EGFR by IHC staining.147e149
However, at present there is no definitive clinical data to
suggest a difference in efficacy for anti-EGFR therapy in
HPV-positive compared to HPV-negative patients.150
Conclusion and future directions
Sequencing efforts and integrative genomics have revealed
a great deal about the molecular abnormalities that un-
derlie HNSCC. Unfortunately, they have also demonstrated
marked heterogeneity, which will make optimizing thera-
peutic intervention difficult. In HNSCC, oncogenic muta-
tions are rare and mutations in tumor suppressor genes
dominate. Restoring function of a tumor suppressor phar-
macologically is difficult. Targeting these alterations may
require exploring synthetic lethal approaches.43 Although
any individual tumors may still have some targetable al-
terations (i.e. amplification or mutation in a known onco-
gene), it is unclear in many cases if these are passengers or
driving events.45 Furthermore, oncogenic pathways can be
activated by non-genetic mechanisms, which would not
have been detected by genomic efforts. Now that a genetic
blueprint for HNSCC has been completed, the challenge
moving forward will be to identify ways to use this infor-
mation to develop improved diagnostic and therapeutic
modalities.
Conflict of interest
The authors have no conflict of interest to disclose.
Acknowledgments
We thank Dr. Nancy Lee for thoughtful discussions. T.A.C.
was partially supported by the Adenoid Cystic Carcinoma
Research Foundation (ACCRF) and a grant from the National
Institutes of Health (R21 DE023229).
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.
Estimates of worldwide burden of cancer in 2008: GLOBOCAN
2008. Int J Cancer. Dec 15 2010;127(12):2893e2917.
Understanding the head and neck cancer genome 832. Hashibe M, Brennan P, Chuang SC, et al. Interaction between
tobacco and alcohol use and the risk of head and neck cancer:
pooled analysis in the International Head and Neck Cancer
Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev.
Feb 2009;18(2):541e550.
3. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking
in relation to oral and pharyngeal cancer. Cancer Res. Jun 1
1988;48(11):3282e3287.
4. Chen YJ, Chang JT, Liao CT, et al. Head and neck cancer in
the betel quid chewing area: recent advances in molecular
carcinogenesis. Cancer Sci. Aug 2008;99(8):1507e1514.
5. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular
biology of head and neck cancer. Nat Rev Cancer. Jan 2011;
11(1):9e22.
6. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal
association between human papillomavirus and a subset of
head and neck cancers. J Natl Cancer Inst. May 3 2000;92(9):
709e720.
7. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human
papillomavirus and rising oropharyngeal cancer incidence
in the United States. J Clin Oncol. Nov 10 2011;29(32):
4294e4301.
8. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral
HPV infection in the United States, 2009-2010. JAMA. Feb 15
2012;307(7):693e703.
9. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and
survival of patients with oropharyngeal cancer. N Engl J Med.
Jul 1 2010;363(1):24e35.
10. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics
Review. 2013:1975e2011. Accessed April 2014.
11. Moldovan GL, D’Andrea AD. How the fanconi anemia pathway
guards the genome. Annu Rev Genet. 2009;43:223e249.
12. Rosenberg PS, Alter BP, Ebell W. Cancer risks in fanconi
anemia: findings from the German Fanconi Anemia Registry.
Haematologica. Apr 2008;93(4):511e517.
13. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in
persons with Fanconi anemia. Blood. Feb 1 2003;101(3):
822e826.
14. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective
on the International Fanconi Anemia Registry (IFAR). Blood.
Feb 15 2003;101(4):1249e1256.
15. Alter BP. Radiosensitivity in Fanconi’s anemia patients.
Radiother Oncol. Mar 2002;62(3):345e347.
16. Schneider-Stock R, Giers A, Motsch C, et al. Hereditary p16-
Leiden mutation in a patient with multiple head and neck
tumors. Am J Hum Genet. Jan 2003;72(1):216e218.
17. Tanaka A, Weinel S, Nagy N, et al. Germline mutation in ATR
in autosomal- dominant oropharyngeal cancer syndrome. Am
J Hum Genet. Mar 9 2012;90(3):511e517.
18. Negri E, Boffetta P, Berthiller J, et al. Family history of can-
cer: pooled analysis in the International Head and Neck
Cancer Epidemiology Consortium. Int J Cancer. Jan 15 2009;
124(2):394e401.
19. Copper MP, Jovanovic A, Nauta JJ, et al. Role of genetic
factors in the etiology of squamous cell carcinoma of the head
and neck. Arch Otolaryngol Head Neck Surg. Feb 1995;121(2):
157e160.
20. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G,
Narod SA. Familial risks of squamous cell carcinoma of the
head and neck: retrospective case-control study. BMJ. Sep 21
1996;313(7059):716e721.
21. Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk
factors for head and neck cancer. Semin Oncol. Dec 2004;
31(6):726e733.
22. Sturgis EM, Wei Q. Genetic susceptibilityemolecular epide-
miology of head and neck cancer. Curr Opin Oncol. May 2002;
14(3):310e317.23. Wang LE, Sturgis EM, Eicher SA, Spitz MR, Hong WK, Wei Q.
Mutagen sensitivity to benzo(a)pyrene diol epoxide and the
risk of squamous cell carcinoma of the head and neck. Clin
Cancer Res. Jul 1998;4(7):1773e1778.
24. Cheng L, Eicher SA, Guo Z, Hong WK, Spitz MR, Wei Q.
Reduced DNA repair capacity in head and neck cancer pa-
tients. Cancer Epidemiol Biomarkers Prev. Jun 1998;7(6):
465e468.
25. Hashibe M, McKay JD, Curado MP, et al. Multiple ADH genes
are associated with upper aerodigestive cancers. Nat Genet.
Jun 2008;40(6):707e709.
26. da Silva SD, Ferlito A, Takes RP, et al. Advances and appli-
cations of oral cancer basic research. Oral Oncol. Sep 2011;
47(9):783e791.
27. Cadoni G, Boccia S, Petrelli L, et al. A review of genetic
epidemiology of head and neck cancer related to poly-
morphisms in metabolic genes, cell cycle control and alcohol
metabolism. Acta Otorhinolaryngol Ital. Feb 2012;32(1):1e11.
28. Brunotto M, Zarate AM, Bono A, Barra JL, Berra S. Risk genes
in head and neck cancer: a systematic review and meta-
analysis of last 5 years. Oral Oncol. Mar 2014;50(3):178e188.
29. McKay JD, Truong T, Gaborieau V, et al. A genome-wide as-
sociation study of upper aerodigestive tract cancers con-
ducted within the INHANCE consortium. PLoS Genet. Mar
2011;7(3):e1001333.
30. Chung CH, Parker JS, Karaca G, et al. Molecular classification
of head and neck squamous cell carcinomas using patterns of
gene expression. Cancer Cell. May 2004;5(5):489e500.
31. Walter V, Yin X, Wilkerson MD, et al. Molecular subtypes in
head and neck cancer exhibit distinct patterns of chromo-
somal gain and loss of canonical cancer genes. PLoS One.
2013;8(2):e56823.
32. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of
human breast tumours. Nature. Aug 17 2000;406(6797):
747e752.
33. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic
analysis identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and
NF1. Cancer Cell. Jan 19 2010;17(1):98e110.
34. Roepman P, Wessels LF, Kettelarij N, et al. An expression
profile for diagnosis of lymph node metastases from primary
head and neck squamous cell carcinomas. Nat Genet. Feb
2005;37(2):182e186.
35. Winter SC, Buffa FM, Silva P, et al. Relation of a hypoxia
metagene derived from head and neck cancer to prognosis of
multiple cancers. Cancer Res. Apr 1 2007;67(7):3441e3449.
36. Toustrup K, Sorensen BS, Nordsmark M, et al. Development of
a hypoxia gene expression classifier with predictive impact for
hypoxic modification of radiotherapy in head and neck can-
cer. Cancer Res. Sep 1 2011;71(17):5923e5931.
37. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis
of multiple cancers reveals a common, compact and highly
prognostic hypoxia metagene. Br J Cancer. Jan 19 2010;
102(2):428e435.
38. Eschrich SA, Pramana J, Zhang H, et al. A gene expression
model of intrinsic tumor radiosensitivity: prediction of
response and prognosis after chemoradiation. Int J Radiat
Oncol Biol Phys. Oct 1 2009;75(2):489e496.
39. Onken MD, Winkler AE, Kanchi KL, et al. A surprising cross-
species conservation in the genomic landscape of mouse
and human oral cancer identifies a transcriptional signature
predicting metastatic disease. Clin Cancer Res. Jun 1 2014;
20(11):2873e2884.
40. Overgaard J, Hansen HS, Overgaard M, et al. A randomized
double-blind phase III study of nimorazole as a hypoxic radi-
osensitizer of primary radiotherapy in supraglottic larynx and
pharynx carcinoma. Results of the Danish Head and Neck
84 N. Riaz et al.Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. Feb
1998;46(2):135e146.
41. Toustrup K, Sorensen BS, Lassen P, et al. Gene expression
classifier predicts for hypoxic modification of radiotherapy
with nimorazole in squamous cell carcinomas of the head and
neck. Radiother Oncol. Jan 2012;102(1):122e129.
42. Agrawal N, Frederick MJ, Pickering CR, et al. Exome
sequencing of head and neck squamous cell carcinoma reveals
inactivating mutations in NOTCH1. Science. Aug 26 2011;
333(6046):1154e1157.
43. Stransky N, Egloff AM, Tward AD, et al. The mutational
landscape of head and neck squamous cell carcinoma. Sci-
ence. Aug 26 2011;333(6046):1157e1160.
44. India Project Team of the International Cancer Genome C.
Mutational landscape of gingivo-buccal oral squamous cell
carcinoma reveals new recurrently-mutated genes and mo-
lecular subgroups. Nat Commun. 2013;4:2873.
45. Pickering CR, Zhang J, Yoo SY, et al. Integrative genomic
characterization of oral squamous cell carcinoma identifies
frequent somatic drivers. Cancer Discov. Jul 2013;3(7):
770e781.
46. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of
mutational processes in human cancer. Nature. Aug 22 2013;
500(7463):415e421.
47. Burns MB, Lackey L, Carpenter MA, et al. APOBEC3B is an
enzymatic source of mutation in breast cancer. Nature. Feb
21 2013;494(7437):366e370.
48. Mroz EA, Rocco JW. MATH, a novel measure of intratumor
genetic heterogeneity, is high in poor-outcome classes of
head and neck squamous cell carcinoma. Oral Oncol. Mar
2013;49(3):211e215.
49. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations
occur frequently in gliomas and a subset of tumors derived
from cells with low rates of self-renewal. Proc Natl Acad Sci
USA. Apr 9 2013;110(15):6021e6026.
50. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations
and survival in squamous-cell carcinoma of the head and
neck. N Engl J Med. Dec 20 2007;357(25):2552e2561.
51. Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mu-
tations increases with progression of head and neck cancer.
Cancer Res. Oct 1 1993;53(19):4477e4480.
52. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I,
Bier H. Is the p53 inactivation frequency in squamous cell
carcinomas of the head and neck underestimated? Analysis of
p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts
in 123 unselected tumor specimens. Cancer Res. Mar 15 2003;
63(6):1188e1191.
53. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL,
Casey G. Frequent p53 mutations in head and neck cancer.
Cancer Res. Nov 1 1992;52(21):5997e6000.
54. Brosh R, Rotter V. When mutants gain new powers: news from
the mutant p53 field. Nat Rev Cancer. Oct 2009;9(10):
701e713.
55. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human
cancers: origins, consequences, and clinical use. Cold Spring
Harb Perspect Biol. Jan 2010;2(1):a001008.
56. Braakhuis BJ, Leemans CR, Brakenhoff RH. A genetic pro-
gression model of oral cancer: current evidence and clinical
implications. J Oral Pathol Med. Jul 2004;33(6):317e322.
57. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: lessons from recent developments in the IARC
TP53 database. Hum Mutat. Jun 2007;28(6):622e629.
58. Dittmer D, Pati S, Zambetti G, et al. Gain of function muta-
tions in p53. Nat Genet. May 1993;4(1):42e46.
59. Rothenberg SM, Ellisen LW. The molecular pathogenesis of
head and neck squamous cell carcinoma. J Clin Invest. Jun 1
2012;122(6):1951e1957.60. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in
cancer prognostic factor studies. J Natl Cancer Inst. Jul 20
2005;97(14):1043e1055.
61. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D,
Westra WH. Immunohistochemical detection of p53 protein
accumulation in head and neck cancer: correlation with p53
gene alterations. Hum Pathol. Oct 1999;30(10):1221e1225.
62. Loyo M, Li RJ, Bettegowda C, et al. Lessons learned from
next-generation sequencing in head and neck cancer. Head
Neck. Mar 2013;35(3):454e463.
63. Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, et al.
Prognostic significance of truncating TP53 mutations in head
and neck squamous cell carcinoma. Clin Cancer Res. Jun 1
2011;17(11):3733e3741.
64. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and
locoregional treatment failure in head and neck squamous cell
carcinoma. J Natl Cancer Inst. Nov 6 1996;88(21):1580e1586.
65. Skinner HD, Sandulache VC, Ow TJ, et al. TP53 disruptive
mutations lead to head and neck cancer treatment failure
through inhibition of radiation-induced senescence. Clin
Cancer Res. Jan 1 2012;18(1):290e300.
66. Gudkov AV, Komarova EA. The role of p53 in determining
sensitivity to radiotherapy. Nat Rev Cancer. Feb 2003;3(2):
117e129.
67. van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of
chromosome 9p21-22 early in head and neck cancer progres-
sion. Cancer Res. Mar 1 1994;54(5):1156e1158.
68. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics
portal: an open platform for exploring multidimensional can-
cer genomics data. Cancer Discov. May 2012;2(5):401e404.
69. Center BITGDA. Analysis Overview for Head and Neck Squa-
mous Cell Carcinoma (Primary Solid Tumor Cohort). 2014.
Accessed 18.04.14.
70. Perez-Sayans M, Suarez-Penaranda JM, Gayoso-Diz P, Barros-
Angueira F, Gandara-Rey JM, Garcia-Garcia A. p16(INK4-
a)/CDKN2 expression and its relationship with oral squamous
cell carcinoma is our current knowledge enough? Cancer Lett.
Jul 28 2011;306(2):134e141.
71. Finn R, Crown J, Lang I, et al. Final Results of a Randomized
Phase II Study of PD 0332991, a Cyclin-dependent Kinase
(CDK)-4/6 Inhibitor, in Combination with Letrozole vs
Letrozole Alone for First-line Treatment of ERþ/HER2-
advanced Breast Cancer (PALOMA-1; TRIO-18). Paper Pre-
sented at: AACR; 2014. 2014. San Diego, CA.
72. Musgrove EA, Caldon CE, Barraclough J, Stone A,
Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat
Rev Cancer. Aug 2011;11(8):558e572.
73. Rogers SJ, Harrington KJ, Rhys-Evans P, OC P, Eccles SA.
Biological significance of c-erbB family oncogenes in head and
neck cancer. Cancer Metastasis Rev. Jan 2005;24(1):47e69.
74. Kalyankrishna S, Grandis JR. Epidermal growth factor recep-
tor biology in head and neck cancer. J Clin Oncol. Jun 10
2006;24(17):2666e2672.
75. Hynes NE, Lane HA. ERBB receptors and cancer: the
complexity of targeted inhibitors. Nat Rev Cancer. May 2005;
5(5):341e354.
76. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment.
N Engl J Med. Mar 13 2008;358(11):1160e1174.
77. Schmitz S, Ang KK, Vermorken J, et al. Targeted therapies for
squamous cell carcinoma of the head and neck: current
knowledge and future directions. Cancer Treat Rev. Apr 2014;
40(3):390e404.
78. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus
cetuximab for squamous-cell carcinoma of the head and neck.
N Engl J Med. Feb 9 2006;354(6):567e578.
79. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based
chemotherapy plus cetuximab in head and neck cancer. N
Engl J Med. Sep 11 2008;359(11):1116e1127.
Understanding the head and neck cancer genome 8580. Riaz N, Sherman EJ, Fury M, Lee N. Should cetuximab replace
cisplatin for definitive chemoradiotherapy in locally advanced
head and neck cancer? J Clin Oncol. Jan 10 2013;31(2):
287e288.
81. Riaz N, Sherman E, Koutcher L, et al. Concurrent chemo-
radiotherapywith cisplatin versus cetuximab for squamous cell
carcinoma of the head and neck. Am J Clin Oncol. Jan 7 2014.
82. Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al.
Cisplatin and fluorouracil with or without panitumumab in
patients with recurrent or metastatic squamous-cell carci-
noma of the head and neck (SPECTRUM): an open-label phase
3 randomised trial. Lancet Oncol. Jul 2013;14(8):697e710.
83. Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus
best supportive care versus best supportive care alone in
patients with recurrent or metastatic squamous-cell carci-
noma of the head and neck after failure of platinum-based
chemotherapy: an open-label, randomised phase 3 trial.
Lancet Oncol. Apr 2011;12(4):333e343.
84. Giralt J, Trigo J, S N, et al. Phase 2, randomized trial (CON-
CERT-2) of Panitumumab (PMAB) plus radiotherapy (PRT)
compared with chemoradiotherapy (CRT) in patients (PTS)
with unresected, locally advanced squamous cell carcinoma
of the head and neck (LASCCHN). Ann Oncol. 2012;23(suppl
9):x334e347.
85. Argiris A, Ghebremichael M, Gilbert J, et al. Phase III ran-
domized, placebo-controlled trial of docetaxel with or
without gefitinib in recurrent or metastatic head and neck
cancer: an eastern cooperative oncology group trial. J Clin
Oncol. Apr 10 2013;31(11):1405e1414.
86. Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and
radiotherapy with or without erlotinib in locally advanced
squamous cell carcinoma of the head and neck: a ran-
domized phase II trial. J Clin Oncol. Apr 10 2013;31(11):
1415e1421.
87. Gregoire V, Hamoir M, Chen C, et al. Gefitinib plus cisplatin
and radiotherapy in previously untreated head and neck
squamous cell carcinoma: a phase II, randomized, double-
blind, placebo-controlled study. Radiother Oncol. Jul 2011;
100(1):62e69.
88. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting
the Akt/mammalian target of rapamycin signaling network:
emerging results from the head and neck cancer tissue array
initiative. Clin Cancer Res. Sep 1 2007;13(17):4964e4973.
89. Grandis JR, Tweardy DJ. Elevated levels of transforming
growth factor alpha and epidermal growth factor receptor
messenger RNA are early markers of carcinogenesis in
head and neck cancer. Cancer Res. Aug 1 1993;53(15):
3579e3584.
90. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth
factor receptor copy number alterations correlate with poor
clinical outcome in patients with head and neck squamous
cancer. J Clin Oncol. Jun 1 2007;25(16):2164e2170.
91. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth
factor receptor expression on survival and pattern of relapse
in patients with advanced head and neck carcinoma. Cancer
Res. Dec 15 2002;62(24):7350e7356.
92. Hansen AR, Siu LL. Epidermal growth factor receptor target-
ing in head and neck cancer: have we been just skimming the
surface? J Clin Oncol. Apr 10 2013;31(11):1381e1383.
93. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth
factor receptor mutations in lung cancer. Nat Rev Cancer. Mar
2007;7(3):169e181.
94. Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene
copy number as a predictive biomarker for the efficacy of
cetuximab in combination with chemotherapy in the first-line
treatment of recurrent and/or metastatic squamous cell
carcinoma of the head and neck: EXTREME study. Ann Oncol.
May 2011;22(5):1078e1087.95. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus
cetuximab for locoregionally advanced head and neck cancer:
5-year survival data from a phase 3 randomised trial, and
relation between cetuximab-induced rash and survival. Lan-
cet Oncol. Jan 2010;11(1):21e28.
96. Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y,
Fu YX. Cetuximab-mediated tumor regression depends on
innate and adaptive immune responses. Mol Ther. Jan 2013;
21(1):91e100.
97. Srivastava RM, Lee SC, Andrade Filho PA, et al. Cetuximab-
activated natural killer and dendritic cells collaborate to
trigger tumor antigen-specific T-cell immunity in head and
neck cancer patients. Clin Cancer Res. Apr 1 2013;19(7):
1858e1872.
98. Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of
ERBB2 signaling causes resistance to the EGFR-directed
therapeutic antibody cetuximab. Sci Transl Med. Sep 7
2011;3(99), 99ra86.
99. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape
and significance across 12 major cancer types. Nature. Oct 17
2013;502(7471):333e339.
100. Engelman JA. Targeting PI3K signalling in cancer: opportu-
nities, challenges and limitations. Nat Rev Cancer. Aug 2009;
9(8):550e562.
101. Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P,
Eccles SA. The phosphoinositide 3-kinase signalling pathway
as a therapeutic target in squamous cell carcinoma of the
head and neck. Expert Opin Ther Targets. Aug 2005;9(4):
769e790.
102. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular trans-
formation. Oncogene. Sep 18 2008;27(41):5486e5496.
103. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges
and opportunities. Nat Rev Drug Discov. Feb 2014;13(2):
140e156.
104. Dotto GP. Notch tumor suppressor function. Oncogene. Sep 1
2008;27(38):5115e5123.
105. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in
solid tumours: a little bit of everything but not all the time.
Nat Rev Cancer. May 2011;11(5):338e351.
106. Nicolas M, Wolfer A, Raj K, et al. Notch1 functions as a tumor
suppressor in mouse skin. Nat Genet. Mar 2003;33(3):
416e421.
107. Wang NJ, Sanborn Z, Arnett KL, et al. Loss-of-function mu-
tations in Notch receptors in cutaneous and lung squamous
cell carcinoma. Proc Natl Acad Sci USA. Oct 25 2011;108(43):
17761e17766.
108. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of
NOTCH1 in human T cell acute lymphoblastic leukemia. Sci-
ence. Oct 8 2004;306(5694):269e271.
109. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour
suppressor at the crossroads of cell division, growth and dif-
ferentiation. Nat Rev Cancer. Feb 2008;8(2):83e93.
110. Stacy DR, Ely K, Massion PP, et al. Increased expression of
nuclear factor E2 p45-related factor 2 (NRF2) in head and
neck squamous cell carcinomas. Head Neck. Sep 2006;28(9):
813e818.
111. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1
signaling pathway in cancer. Genes Dev. Oct 15 2013;27(20):
2179e2191.
112. Shibata T, Ohta T, Tong KI, et al. Cancer related mutations in
NRF2 impair its recognition by Keap1-Cul3 E3 ligase and pro-
mote malignancy. Proc Natl Acad Sci USA. Sep 9 2008;105(36):
13568e13573.
113. Martinez VD, Vucic EA, Thu KL, Pikor LA, Lam S, Lam WL.
Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex
components by multiple genetic mechanisms is associated
with poor prognosis in head and neck cancer. Head Neck. Mar
5 2014.
86 N. Riaz et al.114. Solis LM, Behrens C, Dong W, et al. Nrf2 and Keap1 abnor-
malities in non-small cell lung carcinoma and association with
clinicopathologic features. Clin Cancer Res. Jul 15 2010;
16(14):3743e3753.
115. Jiang T, Chen N, Zhao F, et al. High levels of Nrf2 determine
chemoresistance in type II endometrial cancer. Cancer Res.
Jul 1 2010;70(13):5486e5496.
116. Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function
activates Nrf2 and provides advantages for lung cancer cell
growth. Cancer Res. Mar 1 2008;68(5):1303e1309.
117. Abazeed ME, Adams DJ, Hurov KE, et al. Integrative radio-
genomic profiling of squamous cell lung cancer. Cancer Res.
Oct 15 2013;73(20):6289e6298.
118. Dawson MA, Kouzarides T. Cancer epigenetics: from mecha-
nism to therapy. Cell. Jul 6 2012;150(1):12e27.
119. Krivtsov AV, Armstrong SA. MLL translocations, histone modi-
fications and leukaemia stem-cell development. Nat Rev
Cancer. Nov 2007;7(11):823e833.
120. Chung YR, Schatoff E, Abdel-Wahab O. Epigenetic alterations
in hematopoietic malignancies. Int J Hematol. Oct 2012;
96(4):413e427.
121. Wang F, Marshall CB, Ikura M. Transcriptional/epigenetic
regulator CBP/p300 in tumorigenesis: structural and func-
tional versatility in target recognition. Cell Mol Life Sci. Nov
2013;70(21):3989e4008.
122. Morris LG, Ramaswami D, Chan TA. The FAT epidemic: a gene
family frequently mutated across multiple human cancer
types. Cell Cycle. Apr 1 2013;12(7):1011e1012.
123. Morris LG, Kaufman AM, Gong Y, et al. Recurrent somatic
mutation of FAT1 in multiple human cancers leads to aberrant
Wnt activation. Nat Genet. Mar 2013;45(3):253e261.
124. Elmore S. Apoptosis: a review of programmed cell death.
Toxicol Pathol. Jun 2007;35(4):495e516.
125. Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns
of somatic copy number alteration. Nat Genet. Sep 26 2013;
45(10):1134e1140.
126. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic insta-
bilityean evolving hallmark of cancer. Nat Rev Mol Cell Biol.
Mar 2010;11(3):220e228.
127. Patmore HS, Cawkwell L, Stafford ND, Greenman J. Unrav-
eling the chromosomal aberrations of head and neck squa-
mous cell carcinoma: a review. Ann Surg Oncol. Oct 2005;
12(10):831e842.
128. Bockmuhl U, Wolf G, Schmidt S, et al. Genomic alterations
associated with malignancy in head and neck cancer. Head
Neck. Mar 1998;20(2):145e151.
129. Califano J, van der Riet P, Westra W, et al. Genetic progres-
sion model for head and neck cancer: implications for field
cancerization. Cancer Res. Jun 1 1996;56(11):2488e2492.
130. Lee DJ, Schonleben F, Banuchi VE, et al. Multiple tumor-
suppressor genes on chromosome 3p contribute to head and
neck squamous cell carcinoma tumorigenesis. Cancer Biol
Ther. Oct 1 2010;10(7):689e693.
131. Song Y, Li L, Ou Y, et al. Identification of genomic alterations
in oesophageal squamous cell cancer. Nature. Mar 16 2014;
509:91e95.
132. Siebers TJ, Bergshoeff VE, Otte-Holler I, et al. Chromosome
instability predicts the progression of premalignant oral le-
sions. Oral Oncol. Dec 2013;49(12):1121e1128.
133. Giaretti W, Monteghirfo S, Pentenero M, Gandolfo S,
Malacarne D, Castagnola P. Chromosomal instability, DNA
index, dysplasia, and subsite in oral premalignancy as inter-
mediate endpoints of risk of cancer. Cancer Epidemiol Bio-
markers Prev. Jun 2013;22(6):1133e1141.134. Giaretti W, Pentenero M, Gandolfo S, Castagnola P. Chromo-
somal instability, aneuploidy and routine high-resolution DNA
content analysis in oral cancer risk evaluation. Future Oncol.
Oct 2012;8(10):1257e1271.
135. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A
signature of chromosomal instability inferred from gene
expression profiles predicts clinical outcome in multiple
human cancers. Nat Genet. Sep 2006;38(9):1043e1048.
136. Smeets SJ, Brakenhoff RH, Ylstra B, et al. Genetic classifi-
cation of oral and oropharyngeal carcinomas identifies sub-
groups with a different prognosis. Cell Oncol. 2009;31(4):
291e300.
137. Bhattacharya A, Roy R, Snijders AM, et al. Two distinct routes
to oral cancer differing in genome instability and risk for
cervical node metastasis. Clin Cancer Res. Nov 15 2011;
17(22):7024e7034.
138. Mooren JJ, Kremer B, Claessen SM, et al. Chromosome sta-
bility in tonsillar squamous cell carcinoma is associated with
HPV16 integration and indicates a favorable prognosis. Int J
Cancer. Apr 15 2013;132(8):1781e1789.
139. van den Broek GB, Wreesmann VB, van den Brekel MW,
Rasch CR, Balm AJ, Rao PH. Genetic abnormalities associated
with chemoradiation resistance of head and neck squamous
cell carcinoma. Clin Cancer Res. Aug 1 2007;13(15 Pt 1):
4386e4391.
140. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of
human papillomavirus-induced oncogenesis. J Virol. Nov
2004;78(21):11451e11460.
141. Rautava J, Syrjanen S. Biology of human papillomavirus in-
fections in head and neck carcinogenesis. Head Neck Pathol.
Jul 2012;6(suppl 1):S3eS15.
142. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of
human papillomavirus and oropharyngeal cancer. N Engl J
Med. May 10 2007;356(19):1944e1956.
143. Tang KW, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E.
The landscape of viral expression and host gene fusion and
adaptation in human cancer. Nat Commun. 2013;4:2513.
144. Klussmann JP, Weissenborn SJ, Wieland U, et al. Prevalence,
distribution, and viral load of human papillomavirus 16 DNA in
tonsillar carcinomas. Cancer. Dec 1 2001;92(11):2875e2884.
145. Thorland EC, Myers SL, Gostout BS, Smith DI. Common fragile
sites are preferential targets for HPV16 integrations in cer-
vical tumors. Oncogene. Feb 27 2003;22(8):1225e1237.
146. Scheffner M, Werness BA, Huibregtse JM, Levine AJ,
Howley PM. The E6 oncoprotein encoded by human papillo-
mavirus types 16 and 18 promotes the degradation of p53.
Cell. Dec 21 1990;63(6):1129e1136.
147. Mirghani H, Amen F, Moreau F, Guigay J, Hartl DM, Lacau St
Guily J. Oropharyngeal cancers: relationship between
epidermal growth factor receptor alterations and human
papillomavirus status. Eur J Cancer. Apr 2014;50(6):
1100e1111.
148. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined
analysis of HPV-DNA, p16 and EGFR expression to predict
prognosis in oropharyngeal cancer. Int J Cancer. Apr 15 2007;
120(8):1731e1738.
149. Hong A, Dobbins T, Lee CS, et al. Relationships between
epidermal growth factor receptor expression and human
papillomavirus status as markers of prognosis in oropharyn-
geal cancer. Eur J Cancer. Jul 2010;46(11):2088e2096.
150. Rosenthal D, Harari P, Giralt J, et al. Impact of P16 Status on
the Results of the Phase III Cetuximab (Cet)/radiotherapy
(RT). Paper presented at: ASCO. 2014:2014. Chicago, Il.
